ProShare Advisors
SNDX icon

ProShare Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

ProShare Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Sell
14,564
-1,858
-11% -$38.6K ﹤0.01% 1376
2026
Q1 		$384K Sell
16,422
-2,966
-15% -$64.4K ﹤0.01% 1203
2025
Q4 		$407K Buy
19,388
+1,749
+10% +$30.5K ﹤0.01% 1254
2025
Q3 		$271K Sell
17,639
-3,047
-15% -$39.9K ﹤0.01% 1500
2025
Q2 		$194K Sell
20,686
-951
-4% -$10.5K ﹤0.01% 1733
2025
Q1 		$266K Sell
21,637
-5,546
-20% -$78.2K ﹤0.01% 1491
2024
Q4 		$359K Buy
27,183
+6,627
+32% +$113K ﹤0.01% 1491
2024
Q3 		$396K Sell
20,556
-11,044
-35% -$228K ﹤0.01% 1282
2024
Q2 		$649K Buy
31,600
+11,488
+57% +$240K ﹤0.01% 860
2024
Q1 		$479K Buy
20,112
+4,599
+30% +$103K ﹤0.01% 1110
2023
Q4 		$335K Buy
15,513
+2,411
+18% +$37.1K ﹤0.01% 1295
2023
Q3 		$190K Buy
13,102
+80
+0.6% +$1.51K ﹤0.01% 1488
2023
Q2 		$273K Buy
13,022
+1,196
+10% +$24.9K ﹤0.01% 1331
2023
Q1 		$250K Sell
11,826
-1
-0% -$25 ﹤0.01% 1310
2022
Q4 		$301K Buy
11,827
+1,201
+11% +$28K ﹤0.01% 1233
2022
Q3 		$255K Buy
10,626
+433
+4% +$9.71K ﹤0.01% 1242
2022
Q2 		$195K Sell
10,193
-4,443
-30% -$74K ﹤0.01% 1482
2022
Q1 		$254K Sell
14,636
-2,149
-13% -$36.2K ﹤0.01% 1751
2021
Q4 		$367K Buy
16,785
+634
+4% +$11.7K ﹤0.01% 1667
2021
Q3 		$309K Sell
16,151
-4,183
-21% -$69.7K ﹤0.01% 1523
2021
Q2 		$349K Buy
20,334
+5,478
+37% +$100K ﹤0.01% 1787
2021
Q1 		$332K Buy
14,856
+2,581
+21% +$58.3K ﹤0.01% 1741
2020
Q4 		$273K Buy
+12,275
New +$255K ﹤0.01% 1671
2018
Q4 		– Sell
-11,240
Closed -$91K – 1689
2018
Q3 		$91K Sell
11,240
-1,097
-9% -$7.82K ﹤0.01% 1693
2018
Q2 		$87K Sell
12,337
-445
-3% -$4.37K ﹤0.01% 1724
2018
Q1 		$182K Sell
12,782
-2,105
-14% -$22.3K ﹤0.01% 1570
2017
Q4 		$130K Buy
+14,887
New +$147K ﹤0.01% 1712

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

ProShare Advisors's SNDX Position: Q2 2026 in Review

ProShare Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 11% in Q2 2026, selling an estimated $38.6K and leaving 14,564 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

ProShare Advisors first reported a position in SNDX in Q4 2017 and has held it in 27 quarters since. The position peaked at $649K in Q2 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • ProShare Advisors held 14,564 shares of Syndax Pharmaceuticals worth $318K as of Q2 2026.
  • ProShare Advisors sold 1,858 Syndax Pharmaceuticals shares in Q2 2026, an estimated $38.6K.
  • Syndax Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1376 holding.
  • ProShare Advisors first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 27 quarters since.
  • ProShare Advisors's Syndax Pharmaceuticals position peaked at $649K in Q2 2024.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.